Acurx Pharmaceuticals (ACXP) Registration Filing summary

Company overview and business model

• Focuses on developing a new class of small molecule antibiotics targeting difficult-to-treat Gram-positive bacterial infections, including priority pathogens such as C. difficile, MRSA, VRE, and DRSP.

• Utilizes a proprietary approach (GPSSⓇ) to inhibit DNA polymerase IIIC, leading to bacterial cell death.

• Pipeline includes candidates for infections identified as urgent threats by WHO, CDC, and FDA.

• Organized in Delaware in 2017, converted to a corporation in 2021.

Financial performance and metrics

• As of June 30, 2025, had 29,407,041 shares of common stock outstanding and no preferred stock outstanding.

• Aggregate market value of public float was $21.9 million as of June 17, 2025.

• Sold $5,478,786 of securities in the prior 12 months under Form S-3 limitations.

Use of proceeds and capital allocation

• Net proceeds will be used for general corporate purposes, including clinical trials, R&D, working capital, capital expenditures, investments, acquisitions, and collaborations.

• Management has broad discretion over allocation and may invest proceeds in short-term, investment-grade securities or reduce short-term debt.